Melanie M. Frigault Translational Medicine, R&D Oncology AstraZeneca Biography Publications Institution JoVE Articles Melanie M. Frigault has not added a biography. If you are Melanie M. Frigault and would like to personalize this page please email our Author Liaison for assistance. Publications A Phase Ib Study of the Highly Selective MET-TKI Savolitinib Plus Gefitinib in Patients with EGFR-mutated, MET-amplified Advanced Non-small-cell Lung Cancer Investigational New Drugs. Apr, 2021 | Pubmed ID: 33052556 Mechanisms of Acquired Resistance to Savolitinib, a Selective MET Inhibitor in -Amplified Gastric Cancer JCO Precision Oncology. 2020 | Pubmed ID: 32923890 A Patient-Derived Cell Atlas Informs Precision Targeting of Glioblastoma Cell Reports. 07, 2020 | Pubmed ID: 32668248 Efficacy of Savolitinib Vs Sunitinib in Patients With MET-Driven Papillary Renal Cell Carcinoma: The SAVOIR Phase 3 Randomized Clinical Trial JAMA Oncology. 08, 2020 | Pubmed ID: 32469384 Acalabrutinib Plus Obinutuzumab in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia Cancer Discovery. 03, 2020 | Pubmed ID: 31915195 Acalabrutinib Monotherapy in Patients with Relapsed/refractory Chronic Lymphocytic Leukemia: Updated Phase 2 Results Blood. 04, 2020 | Pubmed ID: 31876911 Acalabrutinib Monotherapy in Patients with Chronic Lymphocytic Leukemia Who Are Intolerant to Ibrutinib Blood Advances. 05, 2019 | Pubmed ID: 31088809 First-in-Human Phase I Study of the Selective MET Inhibitor, Savolitinib, in Patients with Advanced Solid Tumors: Safety, Pharmacokinetics, and Antitumor Activity Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. 08, 2019 | Pubmed ID: 30952639 Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced Papillary Renal Cell Cancer Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. Sep, 2017 | Pubmed ID: 28644771 The MET Inhibitor AZD6094 (Savolitinib, HMPL-504) Induces Regression in Papillary Renal Cell Carcinoma Patient-Derived Xenograft Models Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. Jun, 2015 | Pubmed ID: 25779944 Is Target Validation All We Need? Current Opinion in Pharmacology. Aug, 2014 | Pubmed ID: 25261632 Are Companion Diagnostics Useful? Clinical Chemistry. Jan, 2013 | Pubmed ID: 23193059 Preparação de pelotas de células mononucleares de sangue periférico e plasma de uma única coleta de sangue em locais de ensaio clínico para análise de biomarcadores Paola Marco-Casanova1, Natalia Lukashchuk1, Benedetta Lombardi1, Veerendra Munugalavadla2, Melanie M. Frigault3, Elizabeth A. Harrington1, J. Carl Barrett3, Andrew J. Pierce1 1Translational Medicine, R&D Oncology, AstraZeneca, 2Acerta Pharma, AstraZeneca Group, 3Translational Medicine, R&D Oncology, AstraZeneca JoVE 60776 医学
Preparação de pelotas de células mononucleares de sangue periférico e plasma de uma única coleta de sangue em locais de ensaio clínico para análise de biomarcadores Paola Marco-Casanova1, Natalia Lukashchuk1, Benedetta Lombardi1, Veerendra Munugalavadla2, Melanie M. Frigault3, Elizabeth A. Harrington1, J. Carl Barrett3, Andrew J. Pierce1 1Translational Medicine, R&D Oncology, AstraZeneca, 2Acerta Pharma, AstraZeneca Group, 3Translational Medicine, R&D Oncology, AstraZeneca JoVE 60776 医学
